The global canine arthritis treatment market is poised for substantial expansion, with forecasts indicating a growth from USD 2.50 billion in 2024 to USD 3.77 billion by 2034. This growth, driven by a compound annual growth rate (CAGR) of 4.20%, reflects increasing awareness and demand for effective arthritis treatments for dogs.
The market’s upward trajectory is largely attributed to a rising awareness among pet owners about the benefits of comprehensive arthritis care. The increased availability of pet insurance covering arthritis treatments has enabled pet owners to access a wider range of treatment options. Additionally, the expansion of veterinary services, including acupuncture, hydrotherapy, and physical therapy, has significantly improved the quality of care available to arthritic dogs.
Economic factors also contribute to market growth, as rising disposable income allows pet owners to invest more in advanced arthritis treatments. This trend is further supported by pet insurance companies offering coverage for veterinary expenses, making it easier for owners to afford necessary treatments.
Recent advancements in veterinary pharmaceuticals, such as innovative pain management medications and joint supplements, are enhancing the effectiveness of arthritis relief. Minimally invasive surgical procedures are also gaining popularity, catering to the demand for less invasive yet effective solutions.
Key Insights from the Market Study:
- The oral segment leads the market with a 70% share in 2024.
- Non-steroidal Anti-inflammatory Drugs (NSAIDs) dominate the market with a 72% share.
- The canine arthritis treatment market is experiencing strong growth across various regions:
- India: CAGR of 5.30% through 2034
- Spain: CAGR of 5.50% through 2034
- Italy: CAGR of 4.90% through 2034
- Australia: CAGR of 4.70% through 2034
- France: CAGR of 4.60% through 2034
Browse the Latest Reports from Get Old Source…
Competitive Landscape:
The canine arthritis treatment market is highly competitive, with major companies investing heavily in research and development to innovate new treatments. Notable players include Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, Thorne, NUTRI-VET, American Regent, Inc., and DSM.
Recent Developments:
- January 2023: TVM introduced DogStem, Europe’s first licensed stem cell therapy for canine osteoarthritis.
- May 2019: Elanco launched Galliprant, a novel treatment targeting the EP4 receptor to reduce pain and inflammation in canine osteoarthritis.
- February 2024: Rejuvenate Bio partnered with a leading animal health company to develop groundbreaking gene therapy for canine osteoarthritis.
Market Segmentation:
- By Treatment: NSAIDs, Opioids, Stem Cell Therapy (Allogeneic and Autologous)
- By Route of Administration: Oral, Injectable
- By Distribution Channel: Veterinary Hospitals & Clinics, Retail Pharmacies, Drug Stores, e-Commerce
- By Region: North America, Latin America, Asia Pacific, Middle East and Africa (MEA), Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
